Source: Virtual Congress 2021 – Lung cancer grand round



Rating:

Share or cite this content

Citations should be made in the following way:
A. Tufman (München, Germany). Stage IV adenocarcinoma of the lung with classical epidermal growth factor receptor mutation and a thought-provoking course. Virtual Congress 2021 – Lung cancer grand round

Member's Comments

No comment yet.

Related content which might interest you: Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer Source: Eur Respir J 2005; 25: 329-335 Year: 2005 EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up Source: Eur Respir J 2009; 33: 436-440 Year: 2009 Epidermal growth factor receptor mutation status in advanced non-small cell lung cancer: A single institution experience Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Epidermal growth factor receptor expression in pre-invasive and early invasive bronchial lesions Source: Eur Respir J 2003; 21: 611-615 Year: 2003 Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 Detection of epidermal growth factor receptor mutation in plasma as predictor of gefitinib response in non small cell lung cancer Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008 Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer Source: Eur Respir J 2011; 37: 183-193 Year: 2011 Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis Source: Eur Respir J 2013; 41: 417-424 Year: 2013 Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 A blood-based test for epidermal growth factor receptor mutations in patients with non-small cell lung cancer Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008 A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) as a prognostic factor of survival in patients with lung adenocarcinoma Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 366-372 Year: 2012 TGF-β receptor II in epithelia versus mesenchyme plays distinct roles in the developing lung Source: Eur Respir J 2008; 32: 285-295 Year: 2008 Prognostic significance of epidermal growth factor receptor expression in nonsmall cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002 Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma Source: Eur Respir J 2008; 32: 924-930 Year: 2008 Overexpression of fibroblast growth factor and down-regulation of platelet-derived growth factor correlate with advanced-stage lung fibrosis Source: Annual Congress 2010 - Cell biology and immunology of lung disease Year: 2010